Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: INCB007839 300mg BID|DRUG: Trastuzumab|DRUG: Vinorelbine
Sponsor: Incyte Corporation